ABEO•benzinga•
Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease
Summary
Abeona's Zevaskyn secures timely FDA nod, priced at $3.1 million, with 2025 sales now forecast at $31.6 million and peak U.S. revenue projected at $600 million.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 30, 2025 by benzinga